ASCO Gastrointestinal Cancers Symposium

Results from the phase 3 FRESCO-2 trial substantiate the potential of fruquintinib to offer enhanced survival benefits and improved quality of life for individuals with metastatic colorectal cancer who have undergone prior treatments.

Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.

Clinical characteristics were associated with long-term remission to regorafenib in patients with metastatic colorectal cancer.

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

The updated data of larotrectinib as a treatment in TRK fusion GI cancers continued to demonstrate optimal responses, survival, and safety.

From 2013 to 2022, the use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer, with a trend in patients aged 50 years and younger.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.

Riccardo Lencioni, MD, discusses how the new protocol from the phase 3 EMERALD-1 trial may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma.

Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.

Neoadjuvant camrelizumab in combination with nab-paclitaxel and cisplatin exhibited enhanced pathological complete response compared to solitary chemotherapy in individuals diagnosed with esophageal squamous cell carcinoma.

The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.

The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.

An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.

ASKB589 exhibited anti-tumor activity when used alongside capecitabine and oxaliplatin, along with sintilimab, for the treatment of gastric or gastroesophageal junction cancers.

In patients who were administered nivolumab in conjunction with chemotherapy, there were enhancements observed in both overall survival and progression-free survival compared to those who received chemotherapy alone.

Findings from an observational investigation revealed that the combination of nivolumab and chemotherapy contributed to improve survival in individuals diagnosed with advanced gastrointestinal cancers.

Adding CTX-009 to paclitaxel generated promising responses for patients with advanced biliary tract cancer when given in the second- and third-line settings.

Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.

Findings from the phase 3 NAPOLI 3 trial support the NALIRIFOX regimen as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.

According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

The combination use of encorafenib plus cetuximab and chemotherapy appeared to be safe and effective in treating patients with BRAF V600E-mutant metastatic colorectal cancer.

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.

The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.

SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab, showed early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma.

Modest clinical benefit elicited with or without bevacizumab added to atezolizumab (Tecentriq) plus cisplatin/gemcitabine in biliary tract cancer.

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.

SWOG 1815, which was investigating nab-paclitaxel plus gemcitabine and cisplatin, has missed its primary end point.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better efficacy vs patients treated from 2008 to 2018, according to a real-world study.

Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.